PL2115477T3 - Zastosowanie IGFBP-7 do oceny niewydolności serca - Google Patents
Zastosowanie IGFBP-7 do oceny niewydolności sercaInfo
- Publication number
- PL2115477T3 PL2115477T3 PL08707286T PL08707286T PL2115477T3 PL 2115477 T3 PL2115477 T3 PL 2115477T3 PL 08707286 T PL08707286 T PL 08707286T PL 08707286 T PL08707286 T PL 08707286T PL 2115477 T3 PL2115477 T3 PL 2115477T3
- Authority
- PL
- Poland
- Prior art keywords
- igfbp
- assessment
- heart failure
- heart
- failure
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title 1
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4745—Insulin-like growth factor binding protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07001582 | 2007-01-25 | ||
| EP08707286.4A EP2115477B1 (en) | 2007-01-25 | 2008-01-25 | Use of igfbp-7 in the assessment of heart failure |
| PCT/EP2008/000576 WO2008089994A1 (en) | 2007-01-25 | 2008-01-25 | Use of igfbp-7 in the assessment of heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2115477T3 true PL2115477T3 (pl) | 2015-12-31 |
Family
ID=37810309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08707286T PL2115477T3 (pl) | 2007-01-25 | 2008-01-25 | Zastosowanie IGFBP-7 do oceny niewydolności serca |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20100285491A1 (pl) |
| EP (2) | EP2115477B1 (pl) |
| JP (1) | JP2010517023A (pl) |
| CN (2) | CN101636656A (pl) |
| CA (1) | CA2671298C (pl) |
| DK (1) | DK2115477T3 (pl) |
| ES (1) | ES2548009T3 (pl) |
| HU (1) | HUE025408T2 (pl) |
| PL (1) | PL2115477T3 (pl) |
| WO (1) | WO2008089994A1 (pl) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2115477B1 (en) * | 2007-01-25 | 2015-06-24 | Roche Diagnostics GmbH | Use of igfbp-7 in the assessment of heart failure |
| WO2010096713A2 (en) * | 2009-02-20 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for the diagnosis of age-associated vascular disorders |
| WO2011012268A1 (en) * | 2009-07-27 | 2011-02-03 | Roche Diagnostics Gmbh | Use of mimecan in the assessment of heart failure |
| JP5775874B2 (ja) * | 2009-08-28 | 2015-09-09 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| ES2818138T3 (es) | 2009-12-20 | 2021-04-09 | Astute Medical Inc | Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
| RS54879B1 (sr) * | 2010-02-05 | 2016-10-31 | Astute Medical Inc | Metode i kompozicije za dijagnoze i prognoze oštećenja bubrega i bubrežne insuficijencije |
| EP2796874B1 (en) * | 2010-08-26 | 2017-03-08 | Roche Diagnostics GmbH | Use of biomarkers in monitoring a medication in a subject suffering from heart failure |
| FI20115367A0 (fi) * | 2011-04-15 | 2011-04-15 | Hytest Oy | Menetelmä sydän- ja verisuonitapahtumien määrittämiseksi käyttämällä IGFBP-fragmentteja |
| WO2013053076A1 (en) * | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| EP3088900B1 (en) | 2011-10-17 | 2020-08-12 | Roche Diagniostics GmbH | Troponin as marker for intermittent atrial fibrillation |
| EP2788759B1 (en) | 2011-12-08 | 2019-02-20 | Astute Medical, Inc. | Methods and uses for diagnosis of renal injury and renal failure |
| EP2883057B1 (en) | 2012-08-09 | 2018-12-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Diagnostic of heart failure |
| EP4075143A1 (en) * | 2012-09-12 | 2022-10-19 | Roche Diagnostics GmbH | Identification of patients with abnormal fractional shortening |
| EP2730923A1 (en) * | 2012-11-09 | 2014-05-14 | Roche Diagniostics GmbH | NTproBNP and cTnT based therapy guidance in heart failure |
| EP2929354B1 (en) * | 2012-12-04 | 2018-04-18 | Roche Diagnostics GmbH | Biomarkers in the selection of therapy of heart failure |
| EP4105657B1 (en) | 2013-01-17 | 2024-09-25 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| HRP20190801T1 (hr) * | 2013-06-06 | 2019-08-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Biološki biljeg za rehospitalizaciju nakon srčane insuficijencije |
| EP2843414B1 (en) * | 2013-08-26 | 2018-09-19 | Roche Diagniostics GmbH | Marker for statin treatment stratification in heart failure |
| EA201690731A1 (ru) * | 2013-11-06 | 2016-10-31 | Астьют Медикал, Инк. | Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах |
| CN110007084B (zh) | 2013-12-03 | 2022-11-18 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断和预后的方法和组合物 |
| CN104758922A (zh) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | 纽兰格林制剂的配方 |
| EP3470848A3 (en) * | 2014-01-28 | 2019-05-22 | Roche Diagnostics GmbH | Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides |
| ES2939018T3 (es) | 2014-03-26 | 2023-04-18 | Hoffmann La Roche | IGFBP7 para diagnosticar una disfunción diastólica |
| CN103926401A (zh) * | 2014-03-31 | 2014-07-16 | 瑞莱生物科技（江苏）有限公司 | 一种快速定量检测igfbp-7和timp-2的免疫荧光试纸条及其制备方法 |
| CN105561298A (zh) | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| CN110514846A (zh) * | 2014-10-29 | 2019-11-29 | 豪夫迈·罗氏有限公司 | 用于死亡的风险预测的生物标志物 |
| CN104408717A (zh) * | 2014-11-24 | 2015-03-11 | 北京航空航天大学 | 一种基于着色分离的病理图像颜色质量综合评价方法 |
| WO2016164854A1 (en) | 2015-04-09 | 2016-10-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| BR112018015532A2 (pt) * | 2016-02-29 | 2018-12-26 | Hoffmann La Roche | métodos para o diagnóstico de pré-eclâmpsia, para avaliar a gravidade da pré-eclâmpsia, e para o monitoramento pré-eclâmpsia, usos de biomarcador, kit adaptado para a realização do método e dispositivo adaptado para diagnosticar se uma paciente sofre de pré-eclâmpsia |
| US11243217B2 (en) | 2016-06-06 | 2022-02-08 | Astute Medical, Inc. | Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 |
| KR102149593B1 (ko) * | 2016-06-17 | 2020-08-31 | 에프. 호프만-라 로슈 아게 | 심방 세동 재발의 예측을 위한 순환성 안지오포이에틴-2 (Ang-2) |
| US10865412B2 (en) * | 2016-11-04 | 2020-12-15 | Ottawa Heart Institute Research | Therapeutics targeting IGFBP7 for the treatment or prevention of heart failure and metabolic diseases |
| JP7058331B2 (ja) | 2017-12-13 | 2022-04-21 | エフ．ホフマン－ラ ロシュ アーゲー | 脳卒中の予測のための循環アンジオポエチン－２（Ａｎｇ－２）およびインスリン様増殖因子結合タンパク質７（ＩＧＦＢＰ７） |
| CN112673259B (zh) | 2018-07-20 | 2024-11-22 | 豪夫迈·罗氏有限公司 | 基于igfbp-7的先兆子痫预测 |
| BR112021002445A2 (pt) | 2018-08-10 | 2021-05-04 | F. Hoffmann-La Roche Ag | métodos para prever o risco de acidente vascular cerebral, para aprimorar a precisão da previsão de uma pontuação de risco clínico, para avaliar a eficácia de uma terapia, para identificar um paciente e para monitorar um paciente, usos e kit |
| BR112021002725A2 (pt) | 2018-08-16 | 2021-07-20 | F. Hoffmann-La Roche Ag | métodos para avaliar a fibrilação atrial, para prever o risco de acidente vascular cerebral, para avaliar a eficácia de uma terapia, para identificar um paciente, para monitorar a terapia de anticoagulação e para auxiliar na avaliação da fibrilação atrial, método implementado por computador, kit e uso in vitro |
| JP7333384B2 (ja) | 2018-08-22 | 2023-08-24 | エフ． ホフマン－ラ ロシュ アーゲー | 心房細動の評価における循環ｓｐｏｎ－１（スポンジン－１） |
| CN113396331B (zh) | 2018-08-24 | 2024-10-22 | 豪夫迈·罗氏有限公司 | 心房颤动的评定中以及用于脑卒中预测的循环fgfbp-1(成纤维细胞生长因子结合蛋白1) |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| JP7399431B2 (ja) * | 2019-03-29 | 2023-12-18 | 栄研化学株式会社 | 動脈硬化及び動脈硬化関連疾患マーカー |
| CN120629587A (zh) | 2019-05-23 | 2025-09-12 | 豪夫迈·罗氏有限公司 | HFpEF的IGFBP7比率 |
| EP4196796A1 (en) | 2020-08-14 | 2023-06-21 | F. Hoffmann-La Roche AG | Igfbp7 for the assessment of silent brain infarcts and cognitive decline |
| CN115957301A (zh) * | 2021-10-13 | 2023-04-14 | 中国科学院上海营养与健康研究所 | 一种促进心梗心肌修复的细胞分泌因子及应用 |
| JP2025508481A (ja) | 2022-03-18 | 2025-03-26 | エフ． ホフマン－ラ ロシュ アーゲー | ２型対１型の急性心筋梗塞の早期識別のためのトロポニンマーカーの組合せ |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US686A (en) | 1838-04-13 | Machine foe faking- and goring | ||
| US6174A (en) | 1849-03-13 | Improvement in balances for weighing | ||
| DE3922873A1 (de) | 1989-04-25 | 1990-10-31 | Boehringer Mannheim Gmbh | Spezifische antikoerper gegen troponin t, ihre herstellung und verwendung in einem reagenz zur bestimmung von hermuskelnekrosen |
| US6333397B1 (en) | 1989-04-25 | 2001-12-25 | Roche Diagnostics Gmbh | Monoclonal antibodies to troponin T and their production |
| JPH07132095A (ja) | 1993-06-11 | 1995-05-23 | Nawata Arata | Ｄｎａおよびそのコードする蛋白質 |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US6174686B1 (en) * | 1995-04-18 | 2001-01-16 | Biosite Diagnostics, Inc. | Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays |
| EP1140137A2 (en) * | 1998-12-18 | 2001-10-10 | Scios Inc. | Method for detection and use of differentially expressed genes in disease states |
| JP2002532092A (ja) | 1998-12-18 | 2002-10-02 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | プロスタサイクリン刺激因子−２ |
| US6709855B1 (en) | 1998-12-18 | 2004-03-23 | Scios, Inc. | Methods for detection and use of differentially expressed genes in disease states |
| ES2234560T3 (es) * | 1999-01-06 | 2005-07-01 | Genentech, Inc. | Variante mutante del factor de crecimiento de tipo insulina (igf-i). |
| AU758562B2 (en) * | 1999-01-29 | 2003-03-27 | Roche Diagnostics Gmbh | Method of identifying N-terminal proBNP |
| US7071160B2 (en) | 2000-06-15 | 2006-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Insulin-like growth factor-binding protein |
| US20030119009A1 (en) * | 2001-02-23 | 2003-06-26 | Stuart Susan G. | Genes regulated by MYCN activation |
| US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| DE60233301D1 (de) | 2001-05-04 | 2009-09-24 | Biosite Inc | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
| GB0130557D0 (en) | 2001-12-20 | 2002-02-06 | Serono Internat S A | Proteins |
| AU2003301843A1 (en) | 2002-05-17 | 2004-06-07 | Human Genome Sciences, Inc. | 157 human secreted proteins |
| GB0216191D0 (en) * | 2002-07-11 | 2002-08-21 | Univ Leicester | Plasma urotensin in human heart failure |
| DK2256132T3 (en) | 2003-05-12 | 2015-07-13 | Roche Diagnostics Gmbh | METHOD FOR DETECTION OF proBNP with a monoclonal antibody |
| GB0329288D0 (en) * | 2003-12-18 | 2004-01-21 | Inverness Medical Switzerland | Monitoring method and apparatus |
| US20060003338A1 (en) | 2004-06-30 | 2006-01-05 | Deng David X | System and methods for the management and treatment of vascular graft disease |
| US7659091B2 (en) * | 2004-09-21 | 2010-02-09 | Nourheart, Inc. | Diagnostic marker |
| ITVI20050059A1 (it) | 2005-03-04 | 2006-09-05 | Consorzio Per Gli Studi Universitari In Verona | Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali |
| EP1875248A2 (en) * | 2005-03-29 | 2008-01-09 | Inverness Medical Switzerland GmbH | Device and method of monitoring a patient |
| DE102005014752A1 (de) * | 2005-03-31 | 2006-11-23 | Johannes-Gutenberg-Universität Mainz | Entzündungsmarker und Kombinationen davon als biochemische Marker bei kardiovaskulären Erkrankungen |
| EP1722232A1 (en) * | 2005-05-09 | 2006-11-15 | F.Hoffmann-La Roche Ag | Devices and methods for diagnosing or predicting early stage cardiac dysfunctions |
| EP1731910A1 (en) * | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
| EP2095107B1 (en) * | 2006-11-14 | 2014-07-02 | Alere San Diego, Inc. | Methods for risk assignment |
| EP2115477B1 (en) * | 2007-01-25 | 2015-06-24 | Roche Diagnostics GmbH | Use of igfbp-7 in the assessment of heart failure |
| ATE456797T1 (de) * | 2007-03-06 | 2010-02-15 | Hoffmann La Roche | Verwendung von nogo-c bei der beurteilung von herzversagen |
| CN101627306B (zh) * | 2007-03-08 | 2014-02-05 | 霍夫曼-拉罗奇有限公司 | Slim-1在心力衰竭评估中的用途 |
| WO2011012268A1 (en) * | 2009-07-27 | 2011-02-03 | Roche Diagnostics Gmbh | Use of mimecan in the assessment of heart failure |
-
2008
- 2008-01-25 EP EP08707286.4A patent/EP2115477B1/en active Active
- 2008-01-25 ES ES08707286.4T patent/ES2548009T3/es active Active
- 2008-01-25 CA CA2671298A patent/CA2671298C/en active Active
- 2008-01-25 CN CN200880003100A patent/CN101636656A/zh active Pending
- 2008-01-25 CN CN201610893998.1A patent/CN106908603B/zh active Active
- 2008-01-25 HU HUE08707286A patent/HUE025408T2/hu unknown
- 2008-01-25 DK DK08707286.4T patent/DK2115477T3/en active
- 2008-01-25 EP EP12156343A patent/EP2498095A3/en not_active Withdrawn
- 2008-01-25 PL PL08707286T patent/PL2115477T3/pl unknown
- 2008-01-25 WO PCT/EP2008/000576 patent/WO2008089994A1/en not_active Ceased
- 2008-01-25 JP JP2009546687A patent/JP2010517023A/ja active Pending
-
2009
- 2009-07-16 US US12/504,208 patent/US20100285491A1/en not_active Abandoned
-
2014
- 2014-11-13 US US14/540,165 patent/US20150293122A1/en not_active Abandoned
-
2016
- 2016-10-05 US US15/285,685 patent/US10488422B2/en active Active
-
2019
- 2019-10-10 US US16/598,361 patent/US10996229B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2498095A3 (en) | 2012-11-28 |
| WO2008089994A8 (en) | 2009-05-22 |
| EP2115477B1 (en) | 2015-06-24 |
| CN106908603A (zh) | 2017-06-30 |
| CN106908603B (zh) | 2019-04-02 |
| US20170016918A1 (en) | 2017-01-19 |
| EP2498095A2 (en) | 2012-09-12 |
| DK2115477T3 (en) | 2015-08-10 |
| EP2115477A1 (en) | 2009-11-11 |
| US20150293122A1 (en) | 2015-10-15 |
| CA2671298C (en) | 2020-07-28 |
| US20100285491A1 (en) | 2010-11-11 |
| ES2548009T3 (es) | 2015-10-13 |
| CN101636656A (zh) | 2010-01-27 |
| WO2008089994A1 (en) | 2008-07-31 |
| US10488422B2 (en) | 2019-11-26 |
| CA2671298A1 (en) | 2008-07-31 |
| US20200064359A1 (en) | 2020-02-27 |
| JP2010517023A (ja) | 2010-05-20 |
| US10996229B2 (en) | 2021-05-04 |
| HUE025408T2 (hu) | 2016-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2115477T3 (pl) | Zastosowanie IGFBP-7 do oceny niewydolności serca | |
| ZA201007523B (en) | Heart age assessment | |
| IL212451A0 (en) | Adsorptive structures and the use thereof | |
| IL191773A0 (en) | Cardiac mechanical assessment using ultrasound | |
| GB0701426D0 (en) | Compounds and their use | |
| GB0803018D0 (en) | Therapeutic compounds and their use | |
| GB0818241D0 (en) | Compounds and their use | |
| PL2036882T3 (pl) | Związki o jonach obojnaczych i ich zastosowanie | |
| PL2344449T3 (pl) | Związki arylo-fenylo-sulfonamido-cykloalkilowe i ich zastosowanie | |
| IL208081A0 (en) | Amido - thiophene compounds and their use | |
| EP2171836A4 (en) | LAYER STRUCTURE CONNECTION AND ASSEMBLY | |
| ZA201007395B (en) | Aryl-quinolyl compounds and their use | |
| GB0817208D0 (en) | Therapeutic apsap compounds and their use | |
| EP2307052A4 (en) | ANTI-BETA-2-MICROGLOBULIN AGENTS AND THEIR USE | |
| SI2496415T1 (sl) | Enostransko matirane folije in njihova uporaba | |
| IL212672A (en) | Cycloandesdepsipeptide compounds and their use in drug production | |
| GB0812913D0 (en) | Therapeutic compounds and their use | |
| GB0708507D0 (en) | Substituted phosphonates and their use | |
| HU0700180V0 (en) | Loading area of the mattresses | |
| EP2363132A4 (en) | USE OF SOPHORICOSIDE IN DRUG MANUFACTURE | |
| SI2182954T1 (sl) | Uporaba nor-žolčnih kislin pri zdravljenju arterioskleroze | |
| GB0801319D0 (en) | Compounds and their use | |
| GB0703514D0 (en) | Use of riboflavin | |
| EP2252305A4 (en) | OMENTUM AND ITS USE | |
| GB0802128D0 (en) | Therapeutic compounds and their use |